AGILENT TECHNOLOGIES INC

Agilent CEO & CFO host a live fireside chat at J.P. Morgan’s All Stars Conference, unveiling strategy, ops highlights and future tech plans for its lab‑solutions business.

Agilent boosts its capital market stance with new SEC filings, swapping unregistered notes for freely‑tradeable senior debt and setting a flexible shelf registration for future offerings – enhancing liquidity, investor appeal, and regulatory transpa…

Explore how Agilent Technologies’ investment‑grade credit rating and cutting‑edge analytical platforms position it to thrive amid patent cliffs, market‑access shifts, and biotech M&A, boosting investor confidence.

Agilent’s new EU CE‑mark for PD‑L1 IHC 22C3 (SK006) boosts its precision‑oncology portfolio, driving revenue growth and competitive edge while navigating reimbursement and regulatory hurdles.

Agilent backs HALO X‑ray Technologies to fast‑track a high‑resolution diffraction scanner, boosting airport security and cutting operational costs while opening doors to safer, faster medical imaging.

Agilent’s $600 M debt deal and Biocare acquisition boost its laboratory‑diagnostics portfolio, fueling innovation, global reach, and higher margins in a value‑based healthcare market.

Agilent’s pre‑market jump hides more than momentum—life science growth, diagnostic demand, AI opportunities, and ESG‑driven risk mitigation shape its future.

Agilent Technologies posts 10% revenue growth, 33% operating income jump, and strategic Biocare acquisition—fueling 8‑10% CAGR and AI‑driven diagnostics expansion.

Agilent Technologies reports a 10% revenue rise and expanded margins in Q2 FY 2026, driven by strong Life Sciences, Diagnostics and Ignite platform growth.

Agilent names Michael Buckner as new chief legal officer, boosting governance and IP protection as the company tackles evolving regulatory challenges and future M&A.